JP2025511399A - Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置 - Google Patents

Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置 Download PDF

Info

Publication number
JP2025511399A
JP2025511399A JP2024559031A JP2024559031A JP2025511399A JP 2025511399 A JP2025511399 A JP 2025511399A JP 2024559031 A JP2024559031 A JP 2024559031A JP 2024559031 A JP2024559031 A JP 2024559031A JP 2025511399 A JP2025511399 A JP 2025511399A
Authority
JP
Japan
Prior art keywords
cancer
compound
prmt5 inhibitor
administering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559031A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023196545A5 (https=
JP2025511399A5 (https=
Inventor
ベルモンテス，ブライアン
チャン，エドワード・ラウ・ユエ
ヒューズ，ポール
スレモンズ，キャサリン
スン，ジャン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2025511399A publication Critical patent/JP2025511399A/ja
Publication of JPWO2023196545A5 publication Critical patent/JPWO2023196545A5/ja
Publication of JP2025511399A5 publication Critical patent/JP2025511399A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024559031A 2022-04-08 2023-04-07 Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置 Pending JP2025511399A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329010P 2022-04-08 2022-04-08
US63/329,010 2022-04-08
US202263345736P 2022-05-25 2022-05-25
US63/345,736 2022-05-25
PCT/US2023/017805 WO2023196545A1 (en) 2022-04-08 2023-04-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Publications (3)

Publication Number Publication Date
JP2025511399A true JP2025511399A (ja) 2025-04-15
JPWO2023196545A5 JPWO2023196545A5 (https=) 2025-07-28
JP2025511399A5 JP2025511399A5 (https=) 2025-07-28

Family

ID=86328467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559031A Pending JP2025511399A (ja) 2022-04-08 2023-04-07 Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置

Country Status (14)

Country Link
US (1) US20250228861A1 (https=)
EP (1) EP4504199A1 (https=)
JP (1) JP2025511399A (https=)
KR (1) KR20240169712A (https=)
CN (1) CN119317435A (https=)
AU (1) AU2023249277A1 (https=)
CA (1) CA3255376A1 (https=)
CL (1) CL2024003040A1 (https=)
IL (1) IL315996A (https=)
JO (1) JOP20240223A1 (https=)
MX (1) MX2024012431A (https=)
TW (1) TW202345844A (https=)
WO (1) WO2023196545A1 (https=)
ZA (1) ZA202407596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
EP4637774A1 (en) * 2022-12-21 2025-10-29 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
AU2024356380A1 (en) * 2023-10-06 2026-04-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
TW202519223A (zh) * 2023-10-31 2025-05-16 大陸商康百達（四川）生物醫藥科技有限公司 一種吡啶衍生物及其在醫藥上的應用
WO2025098450A1 (zh) * 2023-11-08 2025-05-15 北京泰德制药股份有限公司 Prmt5抑制剂及其制备方法
WO2025113703A1 (zh) * 2023-12-01 2025-06-05 上海翰森生物医药科技有限公司 四并环类衍生物抑制剂、其制备方法和应用
WO2025157284A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和化疗剂的药物组合物
WO2025157287A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和egfr抑制剂的药物组合物
WO2025176054A1 (zh) * 2024-02-20 2025-08-28 华润医药研究院（深圳）有限公司 三环杂环类化合物及其制备方法和医药用途
WO2025194059A1 (en) * 2024-03-15 2025-09-18 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
WO2025207705A1 (en) * 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025213154A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025250569A1 (en) * 2024-05-29 2025-12-04 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
WO2025265110A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129832A1 (en) * 2019-02-13 2020-08-20 Les Laboratoires Servier Combination therapies for use in treating cancer
JP7787819B2 (ja) * 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors

Also Published As

Publication number Publication date
EP4504199A1 (en) 2025-02-12
AU2023249277A1 (en) 2024-10-17
TW202345844A (zh) 2023-12-01
CL2024003040A1 (es) 2025-02-21
WO2023196545A1 (en) 2023-10-12
ZA202407596B (en) 2025-06-25
US20250228861A1 (en) 2025-07-17
KR20240169712A (ko) 2024-12-03
MX2024012431A (es) 2024-11-08
JOP20240223A1 (ar) 2024-10-06
CN119317435A (zh) 2025-01-14
CA3255376A1 (en) 2023-10-12
IL315996A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP2025511399A (ja) Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置
JP7493521B2 (ja) Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ
EP1339458B1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
Yim Current clinical trials with polo-like kinase 1 inhibitors in solid tumors
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
RU2761953C2 (ru) Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CA2902144C (en) Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
JP2026506429A (ja) Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療
US11890292B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
JP2025537926A (ja) Ｐｒｍｔ５阻害剤及びｍａｔ２ａ阻害剤を使用する癌の処置
JP7303205B2 (ja) 胆道癌を処置するための方法および併用療法
TW202045155A (zh) 用於治療癌症之組合療法
EA052060B1 (ru) Виды лечения рака с применением ингибиторов prmt5, действующих совместно с mta
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
HK40121791A (zh) 利用mta协作的prmt5抑制剂的癌症治疗
JP2013513614A (ja) 膵臓癌を処置する方法
TW202602455A (zh) 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
TW202606706A (zh) 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的胃腸癌治療
JP2026510567A (ja) 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1202419B (en) Combination therapy with a mitotic inhibitor
CZ201690A3 (cs) Inhibitory tyrozinových kináz v kombinaci s cytostatiky a nesteroidními antirevmatiky
HK1202421B (en) Combination therapy with an antitumor antibiotic
HK1188572B (en) Combination therapy with an antitumor alkaloid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260406